Cardiovascular Agents

"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Descriptor ID	D002317
MeSH Number(s)	D27.505.954.411
Concept/Terms	Cardiovascular Agents Cardiovascular Agents Agents, Cardiovascular Cardiovascular Drugs Drugs, Cardiovascular

Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Cardiovascular Agents [D27.505.954.411]

Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.

Bar chart showing 20 publications over 12 distinct years, with a maximum of 5 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2002	0	1	1
2007	2	1	3
2008	0	1	1
2009	1	4	5
2011	1	1	2
2013	0	2	2
2015	0	1	1
2017	0	1	1
2018	1	0	1
2019	1	0	1
2020	1	0	1

Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.

Roshandel G, Kamangar F, Marshall T, Cheng KK, Hemming K, Malekzadeh R. Polypill for prevention of cardiovascular diseases - Authors' reply. Lancet. 2020 02 08; 395(10222):414-415.

View in: PubMed
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019 08 24; 394(10199):672-683.

View in: PubMed
Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.

View in: PubMed
Zou L, Xue Y, Jones M, Heinbockel T, Ying M, Zhan X. The Effects of Quinine on Neurophysiological Properties of Dopaminergic Neurons. Neurotox Res. 2018 07; 34(1):62-73.

View in: PubMed
Nguyen E, Weeda ER, White CM. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. J Clin Pharmacol. 2016 08; 56(8):936-47.

View in: PubMed
Zevallos JC, Yarzebski J, Gonz?lez JA, Banchs HL, Garc?a-Palmieri M, Mattei H, Ayala J, Gonz?lez M, Torres V, Ramos IN, Pericchi LR, Torres DA, Gonz?lez MC, Goldberg RJ. Incidence, in-hospital case-fatality rates, and management practices in Puerto Ricans hospitalized with acute myocardial infarction. P R Health Sci J. 2013 Sep; 32(3):138-45.

View in: PubMed
Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, Penninger JM, Kassiri Z, Vederas JC, Murray AG, Oudit GY. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2013 Jul 01; 2(4):e000249.

View in: PubMed
Felicilda-Reynaldo RF. Block the bleed: pharmacologic therapies for gastroesophageal variceal bleeding. Medsurg Nurs. 2012 Mar-Apr; 21(2):107-10; quiz 111.

View in: PubMed
Rivera FA, Lapid MI, Sampson S, Mueller PS. Safety of electroconvulsive therapy in patients with a history of heart failure and decreased left ventricular systolic heart function. J ECT. 2011 Sep; 27(3):207-13.

View in: PubMed
Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv. 2011 Feb; 4(2):176-82.

View in: PubMed

People

Explore

Similar Concepts

Top Journals